{"name":"Mylan Bertek Pharmaceuticals","slug":"mylan-bertek-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Nebivolol (NEB)","genericName":"Nebivolol (NEB)","slug":"nebivolol-neb","indication":"Hypertension","status":"marketed"},{"name":"Nebivolol and Atenolol","genericName":"Nebivolol and Atenolol","slug":"nebivolol-and-atenolol","indication":"Hypertension","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"apomorphine HCl injection","genericName":"apomorphine HCl injection","slug":"apomorphine-hcl-injection","indication":"Treatment of advanced Parkinson's disease","status":"phase_3"}]}],"pipeline":[{"name":"Nebivolol (NEB)","genericName":"Nebivolol (NEB)","slug":"nebivolol-neb","phase":"marketed","mechanism":"Nebivolol is a selective beta-1 adrenergic receptor antagonist that also has vasodilatory properties through nitric oxide release.","indications":["Hypertension","Heart failure with reduced ejection fraction"],"catalyst":""},{"name":"Nebivolol and Atenolol","genericName":"Nebivolol and Atenolol","slug":"nebivolol-and-atenolol","phase":"phase_3","mechanism":"Nebivolol and atenolol are beta-blockers that reduce heart rate and blood pressure by blocking beta-adrenergic receptors on the heart and blood vessels.","indications":["Hypertension","Angina pectoris","Heart failure","Post-myocardial infarction management"],"catalyst":""},{"name":"apomorphine HCl injection","genericName":"apomorphine HCl injection","slug":"apomorphine-hcl-injection","phase":"phase_3","mechanism":"Apomorphine HCl injection acts as a dopamine agonist, mimicking the action of dopamine in the brain.","indications":["Treatment of advanced Parkinson's disease","Treatment of 'off' episodes in patients with advanced Parkinson's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNbFpHYkVZczNCYUZYWTFuUFpNRFpoZTh0VmtHSFk2bWIyd1V2QThzS3JVMGFNcU9fZHRDOTVJZXBURDFQZWdOd1RLTWhzWVlMaFpWNWc4VGdaT2g2R0dXNXpSYVFLb25CVHVTRnhldUJmLUEwN0E4ZmRhUWxfQzV1aGU3U1FLMC12NGo4Sg?oc=5","date":"2023-03-06","type":"regulatory","source":"Pharma Voice","summary":"FDA ups generics and biosimilar approvals for a shot at lower drug costs - Pharma Voice","headline":"FDA ups generics and biosimilar approvals for a shot at lower drug costs","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQT3IyWThfRkpfLS1NcF9CN0xqdnZydzBjN055aG96cVZKWlJ5Mk1NdjJwcFcwZ2R1eUkwZGdaUEZSWnRUOGhJcUMyUUlOM3ozeEFXLVZjdFRyVklDRlNrU25EdWotX2d0a0NGaV8xRGtRVUZmQUdlZlZYLVZlazJRc0ZBSWJCLWJk?oc=5","date":"2021-08-17","type":"pipeline","source":"In These Times","summary":"When the Plant Closed, These Workers Were Left Behind - In These Times","headline":"When the Plant Closed, These Workers Were Left Behind","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPa0ctNG1yVU5aVU5xZGg2UVFIWnhCV0ZsYzlXUVVDX0l0a2dwUzhiY05Sc2pSa3U3S1hPdWFmTEhtN0UxY0ttSG1VQVpTbUl4WUtUZmRtS0JJcEQ4bjFDM2w0NjZ5U3lvTFd5MVRhMktMaTBLaHd2MHhVTmtyLWJva2d3?oc=5","date":"2016-05-26","type":"pipeline","source":"Fierce Pharma","summary":"Mylan cutting jobs at patch plant - Fierce Pharma","headline":"Mylan cutting jobs at patch plant","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}